A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)

A Two-Part Clinical Study to Evaluate the Effect of Multiple Doses of MK-2828 on Rosuvastatin (Part 1) and Furosemide (Part 2) in Healthy Participants

Researchers are looking for other ways to treat people who have heart failure with preserved ejection fraction (HFpEF). HFpEF is a type of heart failure where the heart becomes stiff and does not relax properly. MK-2828 is a study medicine designed to treat HFpEF.

The main goal of the study is to learn if MK-2828 affects what happens to rosuvastatin or furosemide in the body.

Study Overview

• Status: Active, not recruiting
• Conditions: Healthy
• Intervention / Treatment: Drug: MK-2828; Drug: Rosuvastatin; Drug: Furosemide

• Study Type: Interventional
• Enrollment (Estimated): 39
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Daytona Beach, Florida, United States, 32117
      • Fortrea Clinical Research Unit Inc ( Site 0001)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

• Is in good health
• Has a body mass index (BMI) ≥18 and ≤32 kg/m^2

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

• Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or diseases
• Has a history of cancer (malignancy)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Rosuvastatin + MK-2828; Participants receive rosuvastatin and MK-2828 orally.	Drug: MK-2828; Oral administration; Drug: Rosuvastatin; Oral administration
Experimental: Furosemide + MK-2828; Participants receive furosemide and MK-2828 orally.	Drug: MK-2828; Oral administration; Drug: Furosemide; Oral administration

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Rosuvastatin	Blood samples will be collected to determine the AUC0-inf of rosuvastatin.	At designated time points (up to approximately 2 weeks)
Area Under the Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of Furosemide	Blood samples will be collected to determine the AUC0-inf of furosemide.	At designated time points (up to approximately 2 weeks)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Who Experience an Adverse Event (AE)	An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.	Up to approximately 1 month
Number of Participants Who Discontinue Study Treatment Due to an AE	An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants in who discontinue study treatment due to an AE will be reported.	Up to approximately 2 weeks
Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Rosuvastatin	Blood samples will be collected to determine the AUC0-last of rosuvastatin.	At designated time points (up to approximately 2 weeks)
Area Under the Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUC0-last) of Furosemide	Blood samples will be collected to determine the AUC0-last of furosemide.	At designated time points (up to approximately 2 weeks)
Area Under the Concentration-Time Curve from Time 0 to 24 Hours Postdose (AUC0-24) of Rosuvastatin	Blood samples will be collected to determine the AUC0-24 of rosuvastatin.	At designated time points (up to approximately 24 hours)
Area Under the Concentration-Time Curve from Time 0 to 24 Hours Postdose (AUC0-24) of Furosemide	Blood samples will be collected to determine the AUC0-24 of furosemide.	At designated time points (up to approximately 24 hours)
Maximum Plasma Concentration (Cmax) of Rosuvastatin	Blood samples will be collected to determine the Cmax of rosuvastatin.	At designated time points (up to approximately 2 weeks)
Maximum Plasma Concentration (Cmax) of Furosemide	Blood samples will be collected to determine the Cmax of furosemide.	At designated time points (up to approximately 2 weeks)
Time of the Maximum Plasma Concentration (Tmax) of Rosuvastatin	Blood samples will be collected to determine the Tmax of rosuvastatin.	At designated time points (up to approximately 2 weeks)
Time of the Maximum Plasma Concentration (Tmax) of Furosemide	Blood samples will be collected to determine the Tmax of furosemide.	At designated time points (up to approximately 2 weeks)
Terminal Half-life (t1/2) of Rosuvastatin	Blood samples will be collected to determine the t1/2 of rosuvastatin.	At designated time points (up to approximately 2 weeks)
Terminal Half-life (t1/2) of Furosemide	Blood samples will be collected to determine the t1/2 of furosemide.	At designated time points (up to approximately 2 weeks)
Apparent Total Plasma Clearance (CL/F) of Rosuvastatin	Blood samples will be collected to determine the CL/F of rosuvastatin.	At designated time points (up to approximately 2 weeks)
Apparent Total Plasma Clearance (CL/F) of Furosemide	Blood samples will be collected to determine the CL/F of furosemide.	At designated time points (up to approximately 2 weeks)
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Rosuvastatin	Blood samples will be collected to determine the Vz/F of rosuvastatin.	At designated time points (up to approximately 2 weeks)
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F) of Furosemide	Blood samples will be collected to determine the Vz/F of furosemide.	At designated time points (up to approximately 2 weeks)

Collaborators and Investigators

• Sponsor: Merck Sharp & Dohme LLC
• Investigators: Study Director: Medical Director, Merck Sharp & Dohme LLC

Publications and helpful links

Helpful Links

• Merck Clinical Trials Information

Study record dates

Study Major Dates

• Study Start (Actual): March 18, 2026
• Primary Completion (Estimated): June 7, 2026
• Study Completion (Estimated): June 7, 2026

Study Registration Dates

• First Submitted: February 19, 2026
• First Submitted That Met QC Criteria: February 19, 2026
• First Posted (Actual): February 25, 2026

Study Record Updates

• Last Update Posted (Actual): June 2, 2026
• Last Update Submitted That Met QC Criteria: June 1, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Sulfur Compounds; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Hydrocarbons; Amides; Aniline Compounds; Amines; Pyrimidines; Hydrocarbons, Halogenated; Sulfonamides; Sulfanilamides; Sulfones; Fluorobenzenes; Hydrocarbons, Fluorinated; Rosuvastatin Calcium; Furosemide
• Other Study ID Numbers: 2828-005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No